Annual report [Section 13 and 15(d), not S-K Item 405]

Royalty and Commercial Payment Purchase Agreements - Fully Recovered - Viracta (Details)

v3.26.1
Royalty and Commercial Payment Purchase Agreements - Fully Recovered - Viracta (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Mar. 31, 2021
USD ($)
item
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Agreements      
Payments of consideration under RPAs, AAAs and CPPAs   $ 8,000 $ 53,000
Long-term royalty and commercial payment receivables under the cost recovery method   55,888 55,936
Trade and other receivables, net   4,896 1,839
Income from purchased receivables under cost recovery method   13,744 3,201
Viracta | Royalty Purchase Agreement      
Agreements      
Number of drug candidates | item 2    
Payments of consideration under RPAs, AAAs and CPPAs $ 13,500    
Maximum amount of potential milestones, potential royalties on sales and other payments receivable 54,000    
Amount of maximum consideration retained 5,000    
Maximum amount of potential regulatory and commercial milestones receivable 57,000    
Long-term royalty and commercial payment receivables under the cost recovery method $ 13,500    
Trade and other receivables, net   2,600 1,300
Income from purchased receivables under cost recovery method   $ 13,700 $ 3,200